Union Savings Bank Acquires New Shares in IDEXX Laboratories, Inc. $IDXX

Union Savings Bank acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 3,500 shares of the company’s stock, valued at approximately $2,368,000. IDEXX Laboratories makes up approximately 1.0% of Union Savings Bank’s holdings, making the stock its 17th biggest position.

Other hedge funds have also bought and sold shares of the company. Beacon Investment Advisory Services Inc. boosted its holdings in IDEXX Laboratories by 11.9% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 62,951 shares of the company’s stock worth $42,588,000 after purchasing an additional 6,710 shares during the last quarter. Nordea Investment Management AB raised its stake in IDEXX Laboratories by 114.1% during the 4th quarter. Nordea Investment Management AB now owns 16,597 shares of the company’s stock valued at $11,283,000 after buying an additional 8,845 shares during the last quarter. Procyon Advisors LLC bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $1,966,000. Diversified Trust Co. lifted its holdings in shares of IDEXX Laboratories by 223.5% during the 4th quarter. Diversified Trust Co. now owns 4,199 shares of the company’s stock valued at $2,841,000 after buying an additional 2,901 shares during the period. Finally, Mirabella Financial Services LLP boosted its stake in shares of IDEXX Laboratories by 156.2% in the 3rd quarter. Mirabella Financial Services LLP now owns 4,401 shares of the company’s stock worth $2,806,000 after buying an additional 2,683 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $562.09 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.12 and a quick ratio of 0.82. The firm has a market capitalization of $44.34 billion, a price-to-earnings ratio of 41.39, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. IDEXX Laboratories, Inc. has a one year low of $506.91 and a one year high of $769.98. The business has a fifty day moving average price of $561.66 and a 200-day moving average price of $620.91.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same period in the previous year, the business earned $2.91 earnings per share. IDEXX Laboratories’s quarterly revenue was up 14.3% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Wall Street Zen raised IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, June 13th. Citigroup assumed coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 target price on the stock. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 11th. Finally, UBS Group reduced their price target on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Seven investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $751.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.